Oculotronics Secures Nearly 100 Million Yuan Series A Financing; China’s First Multicenter Randomized Controlled Trial for Ophthalmic Surgical Robots Concludes Concurrently

According to VCBeat, Guangzhou Oculotronics Medical Instrument Co., Ltd.(Oculotronics), a benchmark player in ophthalmic surgical robots, has achieved two major milestones: closing a nearly 100 million yuan Series A financing and completing China’s first multicenter randomized controlled registration trial for ophthalmic surgical robots. The round was led by Essential Capital, with continued follow-on investment from mgcapital and participation from several prominent institutions. Yijia Capital served as the financial and strategic partner. Proceeds will accelerate product registration and commercial rollout, iterate core technologies, and expand the ophthalmic surgical robot product ecosystem.

Founded in 2020, Oculotronics has long specialized in ophthalmic surgical robots, focusing on intelligent upgrades for precision retinal surgery. Its independently developed "Zhuofeng Ophthalmic Surgical Robot" has achieved successive key technical breakthroughs. In 2025, Oculotronics completed the world’s first remote robot-assisted subretinal injection, leveraging low-latency, high-stability 5G technology to perform micron-level precise surgery across 4,200 kilometers from Guangzhou to Xinjiang. This innovative model effectively addresses the uneven distribution of high-quality ophthalmic care, allowing patients in remote areas to receive care from top specialists without traveling. The new remote + intelligent model expands access to premium ophthalmic services, enabling mobile, shareable and replicable high-quality care, advancing equitable healthcare delivery and bringing the benefits of medical innovation to more grassroots patients.

The recently concluded trial is China’s first prospective, multicenter, randomized, open-label, parallel-controlled registration trial in the ophthalmic surgical robot sector, representing Level 1 evidence in evidence-based medicine and a critical step toward regulatory approval. Per China’s National Medical Products Administration requirements for Class III medical devices, high-end innovative medical equipment must undergo rigorous multicenter trials to verify safety and efficacy, with trial design and execution strictly complying with the Good Clinical Practice for Medical Devices.

Oculotronics built its clinical research system in strict alignment with national standards to ensure scientific rigor and reliable data. Preliminary clinical results show that core efficacy and safety indicators meet the trial’s predefined endpoints, with clear trends toward advantages in operational stability and surgical success rates.

Retinal surgery is among the most demanding and technically challenging fields in surgery, requiring micron-level precision in an extremely narrow, delicate anatomical environment under high-magnification microscopy. Most commercially available surgical robots offer millimeter-level accuracy, insufficient for such delicate retinal procedures. Addressing this key clinical pain point, the Zhuofeng robot delivers targeted breakthroughs: end-effector precision of 3-5 microns, telecentric motion accuracy within 100 microns, and a closed-loop control cycle of less than 30 microseconds. Its lightweight, mobile design fits existing operating rooms without additional renovations, lowering barriers to adoption.

Prior to this, Oculotronics completed extensive preclinical studies, including the world’s first subretinal injection in non-human primates and the world’s first 5G remote micron-level ophthalmic surgery in animal trials, laying a robust technical and data foundation for the registration trial.

Through continuous R&D and innovation, Oculotronics has built a portfolio of industry-leading achievements. The company led the development of China’s first group standard for ophthalmic surgical robots, filling an industry gap. Its core technology was named among the "Top 10 Original Advances in Chinese Ophthalmology (2025)," and its AI-assisted surgical research was named a Field Best Paper Finalist at the International Conference on Robotics and Automation (ICRA) in 2024 and a Conference Best Paper Finalist at ICRA in 2025, earning international recognition for its research capabilities. Additionally, the company and its products were selected for the List of Selected Entities for the AI Medical Device Innovation Challenge and the Rui 100 Excellence Program, winning wide recognition from authorities and the industry for its robust innovation capabilities and market value.

Multicenter randomized controlled trials—long, high-cost, and strictly regulated—represent a critical test of a medical innovation’s core strength. Oculotronics adheres to its core values of "truth-seeking and pragmatism," embracing long-termism with the philosophy of "slow is fast." The company focuses on refining core technologies, maintaining strict clinical quality control, and continuously enhancing product reliability, while contributing to the establishment of standardized, regulated development frameworks for China’s ophthalmic surgical robot industry.

These rigorously validated achievements, tested by science, clinical practice and market scrutiny, reflect both the company’s commitment to patient health and its dedication to long-term value creation, setting a benchmark for the innovation and large-scale deployment of domestic high-end intelligent medical equipment. Completed as the company’s pivotal trial concluded, the Series A financing underscores investors’ confidence in Oculotronics’ integrated technology + clinical strengths and validates the value of hard-tech enterprises committed to long-termism and clinical impact.